Circulating melanoma cells in peripheral blood of patients with uveal melanoma before and after different therapies and association with prognostic parameters: A pilot study

Acta Ophthalmologica

Volumn 89, Issue 1, 2011, Pages 17-24

  Suesskind, Daniela ^a   Ulmer, Anja ^a   Schiebel, Ursel ^a   Fierlbeck, Gerhard ^a   Spitzer, Bernhard ^b   Spitzer, Martin S ^a   Bartz Schmidt, Karl U ^a   Grisanti, Salvatore ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

Author keywords

circulating tumour cells; metastases; prognosis; tumour therapy; uveal melanoma

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL SELECTION; CONTROLLED STUDY; ENUCLEATION; FEMALE; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; METASTASIS; PILOT STUDY; PRIORITY JOURNAL; PROGNOSIS; STEREOTAXIS; SYSTEMIC CIRCULATION; UVEA MELANOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; EYE ENUCLEATION; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; IMMUNOMAGNETIC SEPARATION; MALE; MELANOMA; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; OPHTHALMOLOGIC SURGICAL PROCEDURES; PILOT PROJECTS; PROGNOSIS; UVEAL NEOPLASMS; YOUNG ADULT;

EID: 79551573164     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2009.01617.x     Document Type: Article

References (27)

1. AJCC Cancer Staging Manual (2002):, Greene FL, Page DL, Fleming ID, et al. (eds). AJCC Cancer Staging Manual, 6th edn. New York, Berlin, Heidelberg: Springer Verlag.
2. Alix-PanabiÃres C, Riethdorf S, &, Patel K, (2008): Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 14: 5013-5021.
3. Augsburger JJ, (1993): Size classification of posterior uveal malignant melanomas. In:, Laibson PR, Adams RE, Augsburger JJ, et al. (eds). Yearbook of Ophthalmology. St Louis: Mosby, 155-165.
4. Benez A, Schiebel U, &, Fierlbeck G, (2001): Morphologically intact melanoma cells may be detected in peripheral blood of melanoma patients. Recent Results Cancer Res 158: 113-117.
5. Boldin I, Langmann G, Richtig E, et al. (2005): Five-year results of prognostic value of tyrosinase in peripheral blood of uveal melanoma patients. Melanoma Res 15: 503-507.
6. Buchgeister M, Grisanti S, Süsskind D, et al. (2007): A new fixation aid for the radiotherapy of eye tumors. Med Phys 34: 4649-4653.
7. Callejo SA, Antecka E, Blanco PL, et al. (2007): Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye 21: 752-759.
8. Camara O, Kavallaris A, Nöschel H, et al. (2006): Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol 4: 67.
9. Eskelin S, &, Kivelä T, (2001): Authorâ s reply on uveal melanoma: implications of tumor doubling time. Ophthalmology 108: 830-831.
10. Eskelin S, Pyrhönen S, Summanen P, et al. (2000): Tumor doubling times in metastatic malignant melanoma of the uvea. Tumor progression before and after treatment. Ophthamology 107: 1443-1449.
11. Ge MJ, Shi D, Wu QC, et al. (2006): Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in preoperative period. J Cancer Res Clin Oncol 132: 248-256.
12. Koch M, Kienle P, Sauer P, et al. (2004): Hematogenous tumour cell dissemination during colonoscopy for colorectal cancer. Surg Endosc 18: 587-591.
13. Kujala E, &, Kivelä T, (2005): Tumor, node, metastasis classification of malignant ciliary body and choroidal melanoma. Evaluation of the 6th edition and future directions. Ophthalmology 112: 1135-1144.
14. Kujala E, Mäkitie T, &, Kivelä T, (2003): Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 44: 4651-4659.
15. Li Y, Madigan MC, Lai K, et al. (2003): Human uveal melanoma expresses NG2 immunoreactivity. Br J Ophthalmol 87: 629-632.
16. Logan PT, Fernandes BF, Di Cesare S, et al. (2008): Single-cell tumor dormancy model of uveal melanoma. Clin Exp Metastasis 25: 509-516.
17. Manschot WA, &, van Strik R, (1992): Uveal melanoma: therapeutic consequences of doubling times and irradiation results; a review. Int Ophthalmol 16: 91-99.
18. Maruthalacham K, Lash GE, Shenton BK, et al. (2007): Tumour cell dissemination following endoscopic stent insertion. Br J Surg 94: 1151-1154.
19. McLean IW, Zimmerman LE, &, Evans RM, (1978): Reappraisal of Callenderâ s spindle A type of malignant melanoma of choroids and ciliary body. Am J Ophthalmol 86: 557-564.
20. McLean IW, Foster WD, Zimmerman LE, et al. (1983): Modifications of Callenderâ s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 96: 502-509.
21. Â is a predictor for relapse: a preliminary report. World J Surg Oncol 3: 18.
22. Schuster R, Bechrakis NE, Stroux A, et al. (2007): Circulating tumour cells as prognostic factor for distant metastases and survival in patients with primary uveal melanoma. Clin Cancer Res 13: 1171-1178.
23. Singh AD, (2001): Uveal melanoma: implications of tumor doubling time. Ophthalmology 108: 829-830.
24. Singh AD, Bergman L, &, Seregard S, (2005): Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am 18: 75-84.
25. Ulmer A, Schmidt-Kittler O, Fischer J, et al. (2004): Immunomagnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin Cancer Res 10: 531-537.
26. Ulmer A, Beutel J, Süsskind D, et al. (2008): Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 14: 4469-4474.
27. Zimmerman LE, McLean IW, &, Foster WD, (1978): Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells? Br J Ophthalmol 62: 420-425.